Health
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study demonstrating sustained, substantial reductions in glucocorticoid (GC) doses in adults with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont), with approximately 70% of patients achieving GC doses within the physiologic range. These data build upon previously reported one-year results and were presented at the American Associ
About this update from Neurocrine Biosciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Approximately 70% of adult patients treated with CRENESSITY achieved and sustained physiologic‑range glucocorticoid dosing at two years","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"75% of patients originally taking dexamethasone transitioned off this treatment, enabling a more physiologic glucocorticoid regimen without compromising androgen control","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"Findings reinforce durable efficacy and a favorable long‑term safety profile in largest interventional trial to date conducted in classic congenital adrenal hyperplasia","length":168,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":472,"olType":false},{"type":"text","content":"SAN DIEGO, April 22, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study demonstrating sustained, substantial reductions in glucocorticoid (GC) doses in adults with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont), with approximately 70% of patients achieving GC doses within the physiologic range. These data build upon previously reported one-year results and were presented at the American Association of Clinical Endocrinology 2026 Annual Meeting in Las Vegas.","length":612,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Neurocrine Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Neurocrine Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":74,"url":"https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tmdenVtXM7LFmbrt7BNiag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzMA--/https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4","width":400,"height":74}},"href":"https://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Chronic exposure to supraphysiologic GC doses is associated with cardiometabolic comorbidities, bone density reductions, mental health issues and other long-term health risks that contribute to the cumulative treatment burden faced by patients over their lifetimes. Reducing high...